The science is yet to be proven on wide scale of people hence it is currently going through the phase 2b/3 trial and the trial schedule is already been announced by the company. Hence, no rush to buy now, plus cap raise is definitely on the horizon.
Not sure about your 60 to 1 statement, if you are talking about the redomicile to US market, it is on a 100 to 1 ratio.
cheers mate.
GL @Claydoctor
